Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum

Journal of Thoracic Oncology

Volumn 6, Issue 8, 2011, Pages 1320-1329

  Ryu, Jeong Seon ^a,b   Shin, Eun Soon ^c   Nam, Hae Seong ^a,b   Yi, Hyeon Gyu ^a,b   Cho, Jae Hwa ^a,b   Kim, Chul Soo ^b   Kim, Hyun Jung ^a,b   Lee, Jong Eun ^c  

^a Inha University Hospital   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c DNA Link Inc   (South Korea)

Author keywords

CMPK1; Non small cell lung cancer; Pharmacogenetics; Platinum; RRM1

Indexed keywords

CISPLATIN; CYTIDINE MONOPHOSPHATE KINASE 1; DOCETAXEL; GEMCITABINE; PACLITAXEL; PROTEIN KINASE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WILD TYPE;

EID: 80051798346     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182208e26     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Won YJ, Sung J, Jung KW, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009;41:122-131.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
5. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the EuropeanOrganization for Re earch and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909-3917. (Pubitemid 46606203)
6. Wong A, Soo RA, Yong WP, et al. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009;41:77-88.
7. Steed H, Sawyer MB. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 2007;8:803-815.
8. Green H. Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics 2008;9:671-674.
9. Liou JY, Dutschman GE, Lam W, et al. Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 2002;62:1624-1631. (Pubitemid 34408481)
10. Kocabas NA, Aksoy P, Pelleymounter LL, et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008;36:1951-1959.
11. Sabini E, Ort S, Monnerjahn C, et al. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 2003;10:513-519. (Pubitemid 36792901)
12. Johansson M, Brismar S, Karlsson A. Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci USA 1997;94:11941-11945. (Pubitemid 27467821)
13. Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008;3:e3695.
14. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-4737. (Pubitemid 46646245)
15. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-1825. (Pubitemid 44884058)
16. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009;27:5808-5815.
17. Kim HT, Lee JE, Shin ES, et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 2008;26:5972-5979.
18. Bell PA, Chaturvedi S, Gelfand CA, et al. SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques 2002;74:76-77.
19. Soo RA, Wang LZ, Ng SS, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009;63:121-127.
20. Kim SO, Jeong JY, Kim MR, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008;14: 3083-3088.
21. Feng JF, Wu JZ, Hu SN, et al. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer 2009;66:344-349.
22. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2-,2-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-572. (Pubitemid 20356209)